Eton Pharmaceuticals, Inc. (ETON)

NGM – Цена в реальном времени. Валюта: USD

35.70

+0.88 (2.53%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

35.31

-0.39 (-1.09%)

После закрытия: Jun 26, 2026, 6:29 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Eton Pharmaceuticals, Inc. (ETON)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript

Eton Pharmaceuticals Q1 Earnings Call Highlights

Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Видео

No Data

Пресс-релизы

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Announces CFO Succession Plan

Search stocks

Eton Pharmaceuticals, Inc. (ETON)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript

Eton Pharmaceuticals Q1 Earnings Call Highlights

Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Видео

No Data

Пресс-релизы

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Announces CFO Succession Plan